| Revenue Growth | US Acaramidus $253.2M, up 134% YoY; Royalties $20.5M, up from $4.3M. |
|---|---|
| Mgmt Confidence | High confidence in meeting or beating $4B peak-year sales for Acaramidus. |
| Demand Visibility | Identified 500 LGMD2I patients and 600 ADH1 patients ahead of launch. |
| Margin Trends | Operating loss improved to $11.6M from $145.2M loss year-over-year. |
| Op. Leverage | Anticipate margin expansion as Acaramidus scales and three new products launch. |
| Pricing Power | Gross-to-net remains stable; 90% approval rates through payer appeals. |
| Vol vs Price | Growth predominantly driven by first-line new patient starts. |
| Segment Growth | Acaramidus leading brand in Europe; $75M milestone from Bayer partnership. |
| New Clients | Reached 70% of MDA Care Centers; 2,900 physicians have prescribed Acaramidus. |
| Capex & Debt | $1.5B cash on hand; executed share buybacks in September. |
| Regulatory | Three priority reviews: BBP-418 (Nov 27), Infigratinib (Feb 4), Incalorant (May 8). |
| Commentary | Emphasized reducing information asymmetry and using AI for modern commercial execution. |
| New Launches | BBP-418 for LGMD2I, Infigratinib for Achondroplasia, and Incalorant for ADH1. |
Growth
Total revenue $353.2M; US Acaramidus revenue $253.2M, up 134% year-over-year and 14% quarter-over-quarter.
Outlook
Targeting $4B peak sales for Acaramidus and $4B combined for three upcoming launches.
Risks
Management used vague language regarding the specific impact of potential 340B and ASP legislative changes.
The company's earnings call, NASDAQ: BBIO, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
BridgeBio Pharma, Inc.: key numbers
- Share price
- $77.36Close, Nov 16
- Market cap
- $15.1B
- Shares outstanding
- 194.8MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from BridgeBio Pharma, Inc.
All →BridgeBio Pharma CAO Maricel Apuli Sells $146K of Stock
Maricel Apuli, CAO, sold 2,000 shares of BridgeBio Pharma, Inc. at $72.85 a share, worth $146K in total on Oct 30, 2026. Shares held after the trade: 120,687 (-1.6%).
- Value
- $146K
- Shares
- 2,000
- Price
- $72.85
- Role
- CAO
- Holding change
- -1.6%
- Trade date
- Oct 30, 2026
BridgeBio Pharma Q3 2026 Results: Net Loss of $56.7M, Loss Narrows
BridgeBio Pharma reported a significant increase in total revenues to $791.4 million for the first nine months of 2026, driven primarily by net product revenue from Attruby and Beyonttra. Despite the revenue growth, the company maintained a net loss of $382.9 million due to high research and development and selling expenses, though this was an improvement from the $538.3 million loss in the prior year period.
- Key figure
- Net loss $56.7M
BridgeBio Pharma Financial Results
BridgeBio Pharma reported Q3 2026 financial results, highlighted by $353.2 million in total revenue, including $253.2 million from U.S. Attruby net product sales. The company is preparing for three potential product launches in 2026 and 2027 for BBP-418, oral infigratinib, and encaleret, all of which have been granted Priority Review by the FDA.
- Term
- Q3 2026
BridgeBio Pharma Business Update
BridgeBio Pharma announced that the FDA has accepted its New Drug Application (NDA) for oral infigratinib for the treatment of children with achondroplasia and granted it Priority Review. The FDA has assigned a PDUFA target action date of February 4, 2027, for the potential approval of what would be the first oral therapy for this condition. The filing is supported by Phase 3 PROPEL 3 data showing significant improvements in annualized height velocity and body proportionality.
- Counterparty
- FDA
BridgeBio Pharma CEO Neil Kumar Sells $691K of Stock
Neil Kumar, CEO, sold 10,000 shares of BridgeBio Pharma, Inc. at $69.01 to $69.57 a share (average $69.08) in 2 transactions, worth $691K in total on Sep 17, 2026. Shares held after the trade: 495,686 (-0.3%).
- Value
- $691K
- Shares
- 10,000
- Average price
- $69.08
- Role
- CEO
- Holding change
- -0.3%
- Trade date
- Sep 17, 2026